Suchbegriffe: FOLFIRINOX, . Treffer: 5
Riedl, JM; Schwarzenbacher, E; Moik, F; Horvath, L; Gantschnigg, A; Renneberg, F; Posch, F; Barth, DA; Stotz, M; Pichler, M; Hatzl, S; Fandler-Höfler, S; Gressenberger, P; Gary, T; Jost, PJ; Greil, R; Ay, C; Djanani, A; Gerger, A; Schlick, K
Patterns of Thromboembolism in Patients with Advanced Pancreatic Cancer Undergoing First-Line Chemotherapy with FOLFIRINOX or Gemcitabine/nab-Paclitaxel.
Thromb Haemost. 2022; 122(4):633-645
Doi: 10.1055/a-1548-4847
Web of Science
PubMed
FullText
FullText_MUG
Riedl, JM; Posch, F; Horvath, L; Gantschnigg, A; Renneberg, F; Schwarzenbacher, E; Moik, F; Barth, DA; Rossmann, CH; Stotz, M; Schaberl-Moser, R; Pichler, M; Stöger, H; Greil, R; Djanani, A; Schlick, K; Gerger, A
Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis.
Eur J Cancer. 2021; 151: 3-13.
Doi: 10.1016/j.ejca.2021.03.040
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Scheithauer, W; Putora, PM; Grünberger, B; Eisterer, W; Wöll, E; Prager, G; Schaberl-Moser, R; Greil, R; Glatzer, M
Patterns of care in metastatic pancreatic cancer: patient selection in clinical routine.
Therap Adv Gastroenterol. 2019; 12(5):1756284819877635-1756284819877635
Doi: 10.1177/1756284819877635
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Hann, A; Bohle, W; Egger, J; Zoller, W
Feasibility of alternating induction and maintenance chemotherapy in pancreatic cancer.
Sci Rep. 2017; 7(3): 41549-41549.
Doi: 10.1038/srep41549
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Hohla, F; Hopfinger, G; Romeder, F; Rinnerthaler, G; Bezan, A; Stättner, S; Hauser-Kronberger, C; Ulmer, H; Greil, R
Female gender may predict response to FOLFIRINOX in patients with unresectable pancreatic cancer: a single institution retrospective review.
Int J Oncol. 2014; 44(1):319-326
Doi: 10.3892/ijo.2013.2176
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG